Converting-enzyme inhibitor therapy for chronic heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Congestive heart failure (CHF) is a complex syndrome characterized by impaired cardiac function.
• Converting enzyme inhibitors (CEIs) are a class of drugs used to manage hypertension and heart failure.

Purpose of the Study:

• To evaluate the acute and long-term hemodynamic and clinical effects of captopril in patients with congestive heart failure.
• To explore the mechanisms of action of captopril in CHF.

Main Methods:

• Acute and chronic administration of captopril in patients with CHF.
• Hemodynamic measurements including arterial pressure, cardiac index, and ventricular filling pressures.
• Clinical assessment of exercise tolerance and overall patient course.

Main Results:

• Acute captopril administration decreased arterial pressure, vascular resistance, and filling pressures, while increasing cardiac index and ejection fractions.
• Long-term treatment led to further improvements in filling pressures, cardiac output, and exercise tolerance.
• Captopril therapy resulted in a more favorable clinical course compared to placebo.
• Combination therapy with hydralazine enhanced cardiac output and stroke volume without significant adverse effects.

Conclusions:

• Captopril is effective in improving hemodynamic function and clinical outcomes in patients with congestive heart failure.
• The drug's benefits may stem from angiotensin II inhibition, sympatholytic effects, and modulation of vasoactive substances.
• Adverse effects like hypotension are generally manageable, though rare instances of proteinuria, neutropenia, and renal insufficiency may occur.